GV returned for SpyBiotech's $32.5m series A round, as it looks to move its first potential vaccine into the clinic by early next year.

China Merchants Group participated in a series C-plus round for the cancer and inflammatory disease drug developer.

The probiotics developer secured an undisclosed amount as Cargill co-led the first close of a series D round with a $55m target.

Vienna Insurance is among the limited partners for a $48m seed-stage fund aimed at university spinouts in Austria.

Optum Ventures returned to invest in the telehealth software developer’s series A round, which was led by Venrock.

Today's deal net contains news from Boston Metal, Evologic Therapeutics, Lilz, GaitQ, Hemerion Therapeutics and Rebrain.

The share price of Columbia University's cellular oncology drug developer, backed by Osage University Partners, has doubled since it floated.

Tencent co-led online health services provider Yuanxin Technology's series E round with fellow existing investor Sequoia Capital China.

The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.